Brought to you by 
Omthera Pharmaceuticals gets $17.6mm through the sale of debt
12 Mar 2013
Executive Summary
Cardiovascular therapeutics firm Omthera Pharmaceuticals Inc. has raised $17.6mm through the sale of debt and other securities to 13 undisclosed investors. The company is developing Phase III Epanova for dyslipidemia.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Omthera Pharmaceuticals gets $17.6mm through the sale of debt
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice